T0	Participants 177 242	Cutaneous Lymphoma Task Force phase III randomized clinical trial
T1	Participants 335 369	early stages of mycosis fungoides.
T2	Participants 569 625	patients treated with PUVA alone or PUVA and bexarotene.
T3	Participants 764 820	in patients with stage IB and IIA mycosis fungoides (MF)
T4	Participants 996 1029	after 93 of 145 required patients
T5	Participants 1056 1156	the 93 randomized patients, 87 started treatment, 41 received PUVA and 46 received PUVA + bexarotene